HealthQuill Acquisition
Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from the Japanese company.
Drugs Health Pharma

Daiichi Sankyo to buy cancer antibody from Glycotope for $132.5 million

Daiichi Sankyo will buy outright a cancer antibody it had licensed from Glycotope GmbH earlier for $132.5 million, according to a statement from.

Read More
Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to a J&J statement.
Drugs Medical Pharma

Johnson & Johnson to acquire Intra-Cellular Therapies Inc., for $14.6 billion

Johnson & Johnson will acquire Intra-Cellular Therapies Inc., a biopharmaceutical company developing drugs for central nervous system disorders, for $14.6 billion, according to.

Read More
Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of 30%, according to a Securities and Exchange Commission filing.
Drugs Medical Pharma

Biogen Inc., to buy 62m outstanding shares of Sage for $441.7 million

Biogen Inc., plans to buy all outstanding shares totalling 61.17 million of Sage Therapeutics Inc., for $7.22 a share, representing a premium of.

Read More
Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for medicines in the areas of diabetes and obesity.
Uncategorized

Eli Lilly to expand US facility as demand soars for diabetes, obesity medicines

Eli Lilly and Company will invest $3 billion in the US to expand its manufacturing facility to meet a rise in demand for.

Read More
Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.
Drugs Health Pharma

Roche to acquire US-based Poseida Therapeutics for $1.5 billion

Switzerland’s F. Hoffmann-La Roche AG will buy US-based biopharmaceutical company Poseida Therapeutics for $1.5 billion, according to a statement from the Basel-headquartered company.

Read More
AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as Alzheimer’s disease, for $1.4 billion in cash.
Drugs Health Pharma

AbbVie to acquire Aliada for $1.4 billion, bags Alzheimer’s therapy 

AbbVie Inc. will acquire Aliada Therapeutics, a biotechnology company focused on developing drugs to treat diseases of the central nervous system such as.

Read More
Modifi Biosciences, Inc., a Yale University spinout company formed in 2021, has been acquired by Merck & Co. for about $1.3 billion to gain access to therapies that aim to kill cancer cells by modifying cancer DNA selectively.
Drugs Health Pharma

Merck acquires Yale University spinout Modifi Biosciences for up to $1.3 billion

Modifi Biosciences, Inc., a Yale University spinout company formed in 2021, has been acquired by Merck & Co. for about $1.3 billion to.

Read More
H. Lundbeck A/S, a Danish drugmaker, plans to acquire California, US-based Longboard Pharmaceuticals for $2.6 billion, giving it access to a late-stage drug to treat seizures in a group of rare epilepsies.
Drugs Health Pharma

Lundbeck targets epileptic drug, to buy Longboard for $2.6 billion

H. Lundbeck A/S, a Danish drugmaker, plans to acquire California, US-based Longboard Pharmaceuticals for $2.6 billion, giving it access to a late-stage drug.

Read More
The Abu Dhabi National Oil Company, ADNOC, the state-owned oil company of the United Arab Emirates, will buy Germany’s chemicals maker Covestro AG for 11.7 billion euros ($13 billion).
Climate Health Pharma

ADNOC to buy Germany’s chemical producer Covestro for $13 billion

The Abu Dhabi National Oil Company, ADNOC, the state-owned oil company of the United Arab Emirates, will buy Germany’s chemicals maker Covestro AG.

Read More
Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an upfront payment of $850 million.
Drugs Health Pharma

Roche arm to buy breast cancer portfolio from Regor for $850 million

Genentech, a member of the Roche Group, will acquire a portfolio of CDK inhibitors to treat breast cancer from Regor Pharmaceuticals for an.

Read More